Tylenol maker rebounds a day after Trump's unfounded claims about its safety

Core Viewpoint - Kenvue's stock experienced volatility following President Trump's comments linking Tylenol to autism, but it rebounded sharply in premarket trading the next day [1][2]. Group 1: Stock Performance - Kenvue's shares fell by 7.5% on Monday but recovered nearly 5% in premarket trading on Tuesday [2][5]. - The stock's recovery indicates investor confidence despite the negative headlines surrounding Tylenol [4]. Group 2: Company Response - Kenvue has disputed any connection between Tylenol and autism, emphasizing the potential risks for pregnant women who might avoid the medication [3]. - The company highlighted that avoiding Tylenol could lead to dangerous alternatives for managing fevers during pregnancy [3]. Group 3: Market Context - The announcement from Trump relied on existing studies rather than new research, which may limit the long-term impact on Tylenol consumption [2][4]. - Analyst Filippo Falorni from Citi Investment Research noted a limited risk of new lawsuits but acknowledged potential negative effects on Tylenol consumption due to the publicity [4].